Heron Therapeutics Inc., of Redwood City, Calif., said it started a second phase II trial of HTX-011, its Biochronomer-formulated long-acting formulation of local anesthetic bupivacaine in a fixed-dose combination with anti-inflammatory meloxicam for the prevention of postoperative pain.